contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


biogaias-preliminary-results-for-the-third-quarter-did-not-reach-market-expectations

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

BioGaia is a biotechnology company operating in the pharmaceutical industry and focuses on the development, manufacturing and distribution of probiotics for health and well-being. The company's products are aimed at individuals and healthcare institutions. The business is global with a primary presence in Europe, North America and Asia. BioGaia was founded in 1990 and is headquartered in Stockholm.

BioGaia

(Figures in the brackets refer to the same period the previous year) During the third quarter of 2024, BioGaia will record a non-cash impairment of SEK 51.2 million, relating to the acquisition...

(Figures in the brackets refer to the same period the previous year) During the third quarter of 2024, BioGaia will record a non-cash impairment of SEK 51.2 million, relating to the acquisition of MetaboGen AB. The impairment loss is mainly caused by a clinical study that did not meet its primary endpoints which resulted in updated assumptions of the impairment model. The study aimed to prove the efficacy of a next-generation probiotic product for individuals with metabolic syndrome.For the third quarter, sales are preliminarily estimated at SEK 304 million (318), a decrease of 4%. Sales in the third quarter have been negatively impacted by lower demand mainly in EMEA. The operating profit for the third quarter is preliminarily estimated at SEK 41 million (120), a decrease of 65%. Operating profit excluding the impairment loss for the third quarter decreased by 23% to SEK 92.6 millionBioGaia publishes the interim report for quarter three on Tuesday, October 22, 2024, at 08:00 am CEST, followed by an audiocast at 09:30 am CEST.Follow us: Subscribe to BioGaia press releases&nbsp;here&nbsp;(<a href="https://www.biogaiagroup.com/newsroom/subscribe-to-press-releases">https://www.biogaiagroup.com/newsroom/subscribe-to-press-releases</a>) LinkedIn here&nbsp;(<a href="https://www.linkedin.com/company/biogaia-ab/">https://www.linkedin.com/company/biogaia-ab/</a>)Contacts: Alexander Kotsinas, CFO Email: alexander.kotsinas@biogaia.com Phone: +46&nbsp;735 00 11 11 Mikaela Idermark Stern, Corporate Communications Email: mikaela.idermark.stern@biogaia.com Phone: +46 730 95 61 50About BioGaia BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com&nbsp;(<a href="https://www.biogaiagroup.com/">https://www.biogaiagroup.com/</a>)This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at 10:00 p.m. CEST on October 17, 2024.

BioGaia's preliminary results for the third quarter did not reach market expectations